GT
EWTX icon

Glenmede Trust’s Edgewise Therapeutics EWTX Stock Holding History

Glenmede Trust’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$606K Buy
+19,224
New +$554K ﹤0.01% 895
2025
Q1 		$480K Sell
21,809
-110
-0.5% -$2.89K ﹤0.01% 923
2024
Q4 		$585K Buy
21,919
+3,834
+21% +$122K ﹤0.01% 874
2024
Q3 		$483K Buy
+18,085
New +$360K ﹤0.01% 943

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Glenmede Trust's EWTX Position: Q1 2026 in Review

Glenmede Trust opened a new position in Edgewise Therapeutics (EWTX) in Q1 2026: 19,224 shares worth $606K. The stake represents ﹤0.01% of the portfolio and ranks #895 among its holdings. This is a return to the name: Glenmede Trust previously reported a position in EWTX as recently as Q1 2025.

Glenmede Trust first reported a position in EWTX in Q3 2024 and has held it in 4 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Glenmede Trust held 19,224 shares of Edgewise Therapeutics worth $606K as of Q1 2026.
  • Edgewise Therapeutics was a new Glenmede Trust position in Q1 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #895 holding.
  • Glenmede Trust first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.